Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer.

NEW HAVEN, CT – Artizan Biosciences, Inc. (“Artizan”), a biotechnology company at the frontier of microbiome precision medicine, today announced the appointment of Bridget Martell, M.A., M.D., as President and Chief Executive Officer. Dr. Martell is a seasoned biopharmaceutical executive with high-impact, results-oriented breadth and depth in clinical development, medical affairs, and business development across a range of therapeutic areas from first-in-human through approval and commercialization. She succeeds James (Jimmy) Rosen, M.B.A., M.S.P.H., in the roles.

Dr. Martell brings extensive scientific acumen to her leadership roles and has been a pivotal leader or major contributor in the success of six marketed products: Kadcyla^®, Elelyso^®, Intermezzo^®, the trastuzumab biosimilar Ogivri^®, as well as secondary indications for Pradaxa^® and Sutent^®. She has held leadership and C-suite executive roles at companies including Kura Oncology, where she led the menin inhibitor program through a period of rapid growth and at Juniper Pharmaceuticals, where she led development of unique combined drug/device technology that was out-licensed for $131M. Dr. Martell is a currently a member of the Board of Directors at Achieve Life Sciences and serves as a Venture Partner at AlleyCorp’s Healthcare Fund.